Barclays downgrades Polypeptide after strong H1 rally, Samsung offer
Barclays downgraded Polypeptide Group AG to “equal weight” from “overweight,” citing the stock’s strong year-to-date outperformance, which it said was well justified after the company delivered a high-single-digit percentage sales and underlying EBITDA beat alongside raised full-year guidance in the first half of 2026. The brokerage raised its price target to 44.31 Swiss francs per ...
We haven't written up this one. Hellenic Shipping News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
